Syros Pharmaceuticals, Inc. (SYRS)

Market Cap	815.71K
Revenue (ttm)	386.00K
Net Income (ttm)	-97.82M
Shares Out	26.83M
EPS (ttm)	-2.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	312,942
Average Volume	67,291,073
Open	0.0261
Previous Close	0.0295
Day's Range	0.0253 - 0.0300
52-Week Range	0.0250 - 6.9300
Beta	1.31
RSI	31.59
Earnings Date	Mar 21, 2025

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 68
• Stock Exchange: OTCMKTS
• Ticker Symbol: SYRS

Financial Performance

In 2023, Syros Pharmaceuticals's revenue was $9.94 million, a decrease of -33.23% compared to the previous year's $14.88 million. Losses were -$164.57 million, 73.9% more than in 2022.